Sotorasib is a targeted therapy medication used to treat non-small cell lung cancer (NSCLC) that has a specific genetic mutation called KRAS p.G12C. This medication works by blocking the abnormal KRAS protein that helps cancer cells grow and spread. It is used in patients who have already received previous treatment for their locally advanced or metastatic lung cancer. The medication is taken orally and is designed to specifically target cancer cells with this particular genetic mutation, potentially leading to fewer side effects compared to traditional chemotherapy.

Non-small Cell Lung Cancer (NSCLC) – A type of lung cancer that begins in the cells of the lungs and can spread to other parts of the body. NSCLC specifically with KRAS G12C mutation is a distinct form where there is a specific change in the KRAS gene at position G12C. This cancer typically starts in the outer parts of the lungs in the cells that line the airways. The disease can progress from a localized form to become locally advanced, where it grows into nearby structures, or metastatic, where it spreads to distant parts of the body. In its advanced stages, the cancer can grow into nearby tissues and form tumors in other organs.